Lisa L. Smith

发表

Obstacle Avoidance in Collective Robotic Search Using Particle Swarm Optimization

Ganesh K. Venayagamoorthy, Phillip G. Holloway, Lisa L. Smith, 2006 .

Abstract 1823: AZ20, a novel potent and selective inhibitor of ATR kinase with in vivo antitumour activity

Lisa L. Smith, P. Caie, X. Jacq, 2012 .

Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia.

Lisa L. Smith, J. Byrd, F. Awan, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol.

Jeffrey A Jones, Lisa L. Smith, M. Grever, 2012, Blood.

development tool for human chronic lymphocytic leukemia Characterization of the TCL-1 transgenic mouse as a preclinical drug

Lisa L. Smith, M. Grever, J. Byrd, 2013 .

Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia.

Lisa L. Smith, M. Grever, J. Byrd, 2006, Blood.

BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia.

Jeffrey A Jones, Lisa L. Smith, M. Grever, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions.

Lisa L. Smith, M. Grever, J. Byrd, 2004, Blood.

Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia.

Lisa L. Smith, M. Grever, J. Byrd, 2006, Blood.

The discovery and optimisation of pyrido[2,3-d]pyrimidine-2,4-diamines as potent and selective inhibitors of mTOR kinase.

Lisa L. Smith, I. Hickson, G. Smith, 2009, Bioorganic & medicinal chemistry letters.

Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab.

Lisa L. Smith, J. Byrd, I. Flinn, 2003, Cancer research.

AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity.

Lisa L. Smith, C. Chresta, S. Guichard, 2010, Cancer research.

Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL.

Adam R. Johnson, Lisa L. Smith, J. Byrd, 2018, Blood.

Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy.

Jeffrey A Jones, Emanuela M. Ghia, Lisa L. Smith, 2014, Blood.

The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation.

Lisa L. Smith, J. Byrd, F. Awan, 2018, Cancer discovery.

Targeting BTK through microRNA in chronic lymphocytic leukemia.

Lisa L. Smith, J. Byrd, A. Bottoni, 2016, Blood.

LYMPHOID NEOPLASIA Targeting BTK through microRNA in chronic lymphocytic leukemia

Lisa L. Smith, J. Byrd, A. Bottoni, 2016 .

Rituximab and 17‐allylamino‐17‐demethoxygeldanamycin induce synergistic apoptosis in B‐cell chronic lymphocytic leukaemia

Lisa L. Smith, M. Grever, J. Byrd, 2007, British journal of haematology.

The Eµ-Myc/TCL1 Transgenic Mouse As a New Aggressive B-Cell Malignancy Model Suitable for Preclinical Therapeutics Testing

Lisa L. Smith, J. Byrd, A. Johnson, 2015 .

Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells.

Lisa L. Smith, J. Byrd, L. J. Lee, 2008, Blood.

with p53 mutations and deletions Alemtuzumab is an effective therapy for chronic lymphocytic leukemia

Lisa L. Smith, M. Grever, J. Byrd, 2013 .

Title: Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1 selective pressure in T-lymphocytes Short Title: Ibrutinib is an immunomodulatory ITK inhibitor

Lisa L. Smith, M. Caligiuri, J. Byrd, 2016 .

Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia.

Jeffrey A Jones, Lisa L. Smith, M. Grever, 2013, Leukemia research.

response to therapy distinct molecular characteristics and does not indicate a suboptimal Prolonged lymphocytosis during ibrutinib therapy is associated with

Jeffrey A Jones, Emanuela M. Ghia, Lisa L. Smith, 2014 .

Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL).

Lisa L. Smith, J. Byrd, A. Johnson, 2014, Blood.

Genetic heterogeneity of diffuse large B-cell lymphoma

David Dunson, Ting Ni, Anjishnu Banerjee, 2013, Proceedings of the National Academy of Sciences.

Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease.

Jeffrey A Jones, Lisa L. Smith, M. Grever, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Epigenetic Profiling in Chronic Lymphocytic Leukemia Reveals Novel Methylation Targets

Lisa L. Smith, J. Byrd, C. Plass, 2004, Cancer Research.

Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.

Jeffrey A Jones, Lisa L. Smith, M. Grever, 2015, JAMA oncology.

A Novel Celecoxib Derivative , OSU 03012 , Induces Cytotoxicity in Primary CLL Cells and Transformed B-cell Lymphoma via a Caspase and Bcl-2 Independent Mechanism

Lisa L. Smith, J. Byrd, N. Heerema, 2004 .

A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma.

Lisa L. Smith, P. Tamboli, E. Jonasch, 2012, European urology.

independent mechanism - Bcl-2 CLL cells and transformed B-cell lymphoma cell line via a caspase- and A novel celecoxib derivative, OSU03012, induces cytotoxicity in primary

Lisa L. Smith, M. Grever, J. Byrd, 2013 .

A novel celecoxib derivative, OSU03012, induces cytotoxicity in primary CLL cells and transformed B-cell lymphoma cell line via a caspase- and Bcl-2-independent mechanism.

Lisa L. Smith, M. Grever, J. Byrd, 2004, Blood.

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.

Jeffrey A Jones, Lisa L. Smith, M. Caligiuri, 2013, Blood.

Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma

Lisa L. Smith, J. Byrd, A. Johnson, 2009, Leukemia & lymphoma.

Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma

Lisa L. Smith, J. Byrd, A. Johnson, 2009 .

Eμ-TCL1xMyc: A Novel Mouse Model for Concurrent CLL and B-Cell Lymphoma

Lisa L. Smith, J. Byrd, R. Bundschuh, 2019, Clinical Cancer Research.

Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia.

Lisa L. Smith, J. Byrd, A. Johnson, 2015, Blood.

Activated NKT Cells and NK Cells Render T Cells Resistant to Myeloid-Derived Suppressor Cells and Result in an Effective Adoptive Cellular Therapy against Breast Cancer in the FVBN202 Transgenic Mouse

Lisa L. Smith, H. Bear, A. Yacoub, 2011, The Journal of Immunology.

Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway.

Lisa L. Smith, J. Byrd, A. Johnson, 2010, Blood.

Modulation of immune checkpoint molecule expression in mantle cell lymphoma

Lisa L. Smith, J. Byrd, A. Johnson, 2019, Leukemia & lymphoma.

The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia

Lisa L. Smith, R. Ulrich, J. Byrd, 2016, Clinical Cancer Research.

The Bruton's Tyrosine Kinase (BTK) Inhibitor ARQ 531 Effectively Inhibits Wild Type and C481S Mutant BTK and Is Superior to Ibrutinib in a Mouse Model of Chronic Lymphocytic Leukemia

Lisa L. Smith, J. Byrd, A. Johnson, 2016 .

the Development and Expansion of Resistant Subclones Precedes Relapse during Ibrutinib Therapy in Patients with CLL

Jeffrey A Jones, Lisa L. Smith, M. Grever, 2016 .

Inhibitors of Bruton's Tyrosine Kinase Reduce Anti-Red Blood Cell Response in a Murine Model of Autoimmune Hemolytic Anemia

Lisa L. Smith, J. Byrd, A. Johnson, 2016 .

The Cyclin Dependent Kinase Inhibitor SCH 727965 Demonstrates Promising Pre-Clinical and Early Clinical Activity in Chronic Lymphocytic Leukemia.

Jeffrey A Jones, Lisa L. Smith, M. Grever, 2009 .

Cancer in the FVBN202 Transgenic Mouse Adoptive Cellular Therapy against Breast Suppressor Cells and Result in an Effective Cells Resistant to Myeloid-Derived Activated NKT Cells and NK Cells Render T

Lisa L. Smith, H. Bear, A. Yacoub, 2011 .

Transgenic Mouse Therapy against Breast Cancer in the FVBN202 Cells and Result in an Effective Adoptive Cellular Cells Resistant to Myeloid-Derived Suppressor Activated NKT Cells and NK Cells Render T

Lisa L. Smith, A. Yacoub, K. Payne, 2011 .

Preliminary Results of a Phase II Study of Flavopiridol (Alvocidib) in Relapsed Chronic Lymphocytic Leukemia (CLL): Confirmation of Clinical Activity in High-Risk Patients and Achievement of Complete Responses (CR).

Jeffrey A Jones, Lisa L. Smith, M. Grever, 2007 .

The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells

Jeffrey A Jones, Lisa L. Smith, M. Grever, 2012, Leukemia.

Ibrutinib Is an Irreversible Molecular Inhibitor of Interleukin-2 Inducible Kinase: Expanding Therapeutic Potential and Modulating a Th1 Selective Pressure in CD4 T-Cells

Jeffrey A Jones, Lisa L. Smith, M. Caligiuri, 2012 .

The discovery and optimisation of pyrido[2,3-d]pyrimidine-2,4-diamines as potent and selective inhibitors of mTOR kinase.

Lisa L. Smith, I. Hickson, G. Smith, 2009, Bioorganic & medicinal chemistry letters.

Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia.

Lisa L. Smith, J. Byrd, F. Awan, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL.

Adam R. Johnson, Lisa L. Smith, J. Byrd, 2018, Blood.

Evaluation of the novel Bruton′s tyrosine kinase (BTK) inhibitor GDC-0853 in chronic lymphocytic leukemia (CLL) with wild type or C481S mutated BTK.

Lisa L. Smith, J. Byrd, A. Johnson, 2016 .

Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia.

Jeffrey A Jones, Lisa L. Smith, M. Grever, 2013, Leukemia research.